Baumgart DC - Search Results

1

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Panés J, et al. Among authors: baumgart dc. Gastroenterology. 2018 Apr;154(5):1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020. Epub 2017 Dec 24. Gastroenterology. 2018. PMID: 29277560 Clinical Trial.

2

Intestinal barrier function.

Baumgart DC, Dignass AU. Baumgart DC, et al. Curr Opin Clin Nutr Metab Care. 2002 Nov;5(6):685-94. doi: 10.1097/00075197-200211000-00012. Curr Opin Clin Nutr Metab Care. 2002. PMID: 12394645 Review.

3

Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis.

Baumgart DC, Wiedenmann B, Dignass AU. Baumgart DC, et al. Inflamm Bowel Dis. 2004 Jul;10(4):421-4. doi: 10.1097/00054725-200407000-00014. Inflamm Bowel Dis. 2004. PMID: 15475751

4

Current biological therapies for inflammatory bowel disease.

Baumgart DC, Dignass AU. Baumgart DC, et al. Curr Pharm Des. 2004;10(32):4127-47. doi: 10.2174/1381612043382413. Curr Pharm Des. 2004. PMID: 15579093 Review.

5

CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway.

Sturm A, Baumgart DC, d'Heureuse JH, Hotz A, Wiedenmann B, Dignass AU. Sturm A, et al. Among authors: baumgart dc. Cytokine. 2005 Jan 7;29(1):42-8. doi: 10.1016/j.cyto.2004.09.007. Cytokine. 2005. PMID: 15579377

6

Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism.

Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU. Baumgart DC, et al. Scand J Gastroenterol. 2005 Aug;40(8):958-64. doi: 10.1080/00365520510015854. Scand J Gastroenterol. 2005. PMID: 16165710

7

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.

Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Baumgart DC, et al. Am J Gastroenterol. 2006 May;101(5):1048-56. doi: 10.1111/j.1572-0241.2006.00524.x. Am J Gastroenterol. 2006. PMID: 16573777

8

The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease.

Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, Gentz E, Molnar T, Nagy F, Lonovics J, Lochs H, Wiedenmann B, Nickel R, Witt H, Dignass A. Baumgart DC, et al. Digestion. 2007;76(3-4):196-202. doi: 10.1159/000112646. Epub 2007 Dec 21. Digestion. 2007. PMID: 18174680

9

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. Baumgart DC, et al. Inflamm Bowel Dis. 2010 Apr;16(4):620-9. doi: 10.1002/ibd.21084. Inflamm Bowel Dis. 2010. PMID: 19714757 Clinical Trial.

10

Impact of pain on health-related quality of life in patients with inflammatory bowel disease.

Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Schirbel A, et al. Among authors: baumgart dc. World J Gastroenterol. 2010 Jul 7;16(25):3168-77. doi: 10.3748/wjg.v16.i25.3168. World J Gastroenterol. 2010. PMID: 20593502 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page